A Phase 1/2 trial called STEP ONE, or ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company's VC-01 lead product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.
http://ift.tt/1AnY4V1
http://ift.tt/1AnY4V1
No comments:
Post a Comment